Department Otorhinolaryngology-Head & Neck Surgery, Himeji St. Mary's Hospital, Himeji, Japan.
Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Auris Nasus Larynx. 2023 Feb;50(1):81-86. doi: 10.1016/j.anl.2022.05.007. Epub 2022 Jun 26.
Combination intranasal drugs with a corticosteroid and antihistamine are available in several countries with better effect than treatments with single agents. However, it remains unclear whether this effect is also seen in Japanese cedar pollinosis (JCP), the most prevalent seasonal allergic rhinitis in Japan. We investigated the effect of an add-on intranasal antihistamine with an intranasal corticosteroid in JCP during the pollen dispersal period. (UMIN000025508) METHODS: We performed a double-blinded, randomized, placebo-controlled trial from March 1 to 14, 2017. Patients (n = 20 per group) received either a mometasone furoate nasal spray (MFNS) plus a levocabastine nasal spray (levocabastine group) or MFNS plus a placebo nasal spray (placebo group). The primary endpoint was the difference in the total nasal symptom score (TNSS) after treatment between the two groups. Differences in the total ocular symptom score, total symptom score, total medication score, total symptom-medication score, and five individual symptoms as well as safety were the secondary endpoints.
The change in the TNSS from baseline was significantly greater in the levocabastine group than in the placebo group. A significant reduction in the TNSS was observed more than 6 days earlier in the levocabastine group than in the placebo group. Such add-on effects were also seen in the secondary endpoints. Both treatments were well-tolerated.
The intranasal antihistamine provided better control of not only nasal symptoms, but also of ocular symptoms, and decreased the need for rescue medications when added to intranasal corticosteroid treatment in JCP patients.
在一些国家,有几种联合鼻腔药物可供使用,这些药物含有皮质类固醇和抗组胺药,其效果优于单一药物治疗。然而,在日本最常见的季节性过敏性鼻炎——日本扁柏花粉症(JCP)中,这种效果是否也存在尚不清楚。我们研究了在花粉散发期间,鼻腔皮质类固醇联合鼻腔抗组胺药作为附加治疗在 JCP 中的效果。(UMIN000025508)
我们于 2017 年 3 月 1 日至 14 日进行了一项双盲、随机、安慰剂对照试验。患者(每组 20 例)接受糠酸莫米松鼻喷雾剂(MFNS)加左卡巴斯汀鼻喷雾剂(左卡巴斯汀组)或 MFNS 加安慰剂鼻喷雾剂(安慰剂组)治疗。主要终点是两组治疗后总鼻部症状评分(TNSS)的差异。次要终点是总眼部症状评分、总症状评分、总用药评分、总症状-用药评分以及五个单项症状的差异以及安全性。
与安慰剂组相比,左卡巴斯汀组治疗后的 TNSS 变化明显更大。左卡巴斯汀组比安慰剂组更早地观察到 TNSS 的显著降低,早于 6 天。这种附加作用在次要终点中也可见到。两种治疗均耐受良好。
与单独使用鼻腔皮质类固醇相比,在 JCP 患者中,鼻腔抗组胺药联合鼻腔皮质类固醇治疗不仅能更好地控制鼻部症状,还能更好地控制眼部症状,并减少对抢救药物的需求。